We found that inhibiting Drp1 attenuates the impairment in skeletal muscle insulin signaling and improves whole‐body glucose tolerance in the setting of obesity‐induced insulin resistance. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.